Luis Alfonso
Gurpide Ayarra
Consultor Médico
Centro de Investigación Médica Aplicada
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (24)
2024
2022
-
YES1 Is a Druggable Oncogenic Target in SCLC
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403
2021
-
Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients
Cytokine, Vol. 141
-
Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma
Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337
2020
-
Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients
Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348
2019
-
Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001
-
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Nature Medicine, Vol. 25, Núm. 3, pp. 470-476
-
Programmed death–ligand 1 expression on direct Pap-stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens
Cancer Cytopathology, Vol. 127, Núm. 7, pp. 470-480
-
The dynamic use of EGFR mutation analysis in cell-free DNA as a follow-up biomarker during different treatment lines in non-small-cell lung cancer patients
Disease Markers, Vol. 2019
2018
-
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319
-
Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer
Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483
2017
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2016
-
Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value
Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694
2015
2014
2013
-
Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein
Cancer Research, Vol. 73, Núm. 1, pp. 139-149
2011
-
Carcinoma-derived Interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation
PLoS ONE, Vol. 6, Núm. 3
-
Tumor-stromal interactions of the bone microenvironment: In vitro findings and potential in vivo relevance in metastatic lung cancer models
Clinical and Experimental Metastasis, Vol. 28, Núm. 8, pp. 779-791
2010
-
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
Molecular Cancer, Vol. 9
-
Selection of extreme phenotypes: The role of clinical observation in translational research
Clinical and Translational Oncology, Vol. 12, Núm. 3, pp. 174-180